Clinical trials: Cisplatin, completed
Mesothelioma
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Primary Objective: To determine the maximum tolerated dose of the combination of cisplatin, imatinib mesylate, and pemetrexed in metastatic malignant mesothelioma.
- Trial name
- NCT00402766
- Testing
- Cisplatin, Imatinib Mesylate, Pemetrexed
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00945451
- Testing
- CK
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Centre Antoine Lacassagne
Immunotherapy, Analgesia
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
To observe the effect of preoperative anti-PD-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative…
- Conditions
- Immunotherapy, Analgesia, NSCLC, Delirium
- Trial name
- NCT05273827
- Testing
- neoadjuvant immunotherapy, Neoadjuvant chemotherapy
- Where
- 3 sites in China
- Volunteers
- 81 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasopharyngeal Carcinoma
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
The objectives of this clinical study are threefold: 1. To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant…
- Trial name
- NCT00379262
- Testing
- Capecitabine, Adjuvant chemotherapy using PF (5-Fluorouracil ), Induction chemotherapy using PF (5-Fluorouracil)
- Where
- 7 sites in China
- Volunteers
- 803 people
- Sponsor
- Hong Kong Nasopharyngeal Cancer Study Group Limited
Antiemetic Therapy
Epidemiological EMESIS-Registry
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major…
- Trial name
- EMESIS (NCT00911222)
- Testing
- non-interventional
- Where
- Germany
- Volunteers
- 1,035 people
- Sponsor
- iOMEDICO AG
Non-squamous Non-small-cell Lung Cancer, Anlotinib
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. The ALTER-0303 trial showed that patients with advanced non-small cell lung cancer (NSCLC) who received…
- Trial name
- NCT04012619
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Sichuan University
Neuroblastoma
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
High-risk neuroblastoma is an aggressive childhood cancer that shows up as a lump or mass in the belly or around the spinal cord in the chest, neck, or pelvis.
- Trial name
- PEPI (NCT00578864)
- Testing
- Protracted Oral Etoposide, Doxorubicin, IV Bolus Etoposide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor College of Medicine
Squamous Cell Carcinoma of Oral Cavity
Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers
Oral cancer is the single largest cancer in males in India. 90-95% cases of oral cancer are Squamous cell carcinomas and many of them present at late stages (T3 and above).
- Trial name
- NCT03923998
- Testing
- Neoadjuvant chemotherapy, Neoadjuvant radiotherapy, Resection and reconstruction
- Where
- India
- Volunteers
- 8 people
- Sponsor
- Indrayani Hospital and Cancer Institute
Gastric Cancer
A Benefit Population Atlas of nICT Versus nCT for LAGC
The purpose of this observational study is to evaluate the impact of different neoadjuvant therapies on patients with locally advanced gastric cancer.
- Trial name
- NCT07098104
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 291 people
- Sponsor
- Cheng Chen
Head and Neck Cancer, Radiotherapy
Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study
About 89%-100% patients with head and neck malignant tumors have radiation mucositis during their radiotherapy. Until now, there is no effective method to prevent mucositis.
- Trial name
- NCT03101514
- Testing
- Kanglaite, chemotherapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Advanced Solid Tumors
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.
HLX07 is a new anti-EGFR monoclonal antibody (mAb) with improved glycosylation pattern.In pre-clinical efficacy studies, HLX-07 is either equivalent or more potent than cetuximab in multiple cancer models without increased…
- Trial name
- HLX07Ib/II (NCT03577704)
- Testing
- HLX07+Gemcitabine+Cisplatin, HLX07+Paclitaxel+Carboplatin, HLX07+mFOLFOX6
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai Henlius Biotech
Salivary Gland Tumors, Head and Neck Cancer
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and…
- Trial name
- NCT02776163
- Testing
- Nedaplatin, Docetaxel, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma
Nimotuzumab (hR3) is an humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01425736
- Testing
- Chemotherapy, Nimotuzumab and Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 91 people
- Sponsor
- Wei Guo
Head and Neck Cancer
Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002932
- Testing
- cisplatin, radiation therapy
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Radiation Therapy Oncology Group
Pancreatic Cancer
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with radiation therapy and/or surgery may kill more tumor cells.
- Trial name
- NCT00003332
- Testing
- cisplatin, gemcitabine hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Head and Neck Squamous Cell Carcinoma (HNSCC)
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
- Trial name
- NCT02764593
- Testing
- Nivolumab, Cisplatin, Cetuximab
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- RTOG Foundation, Inc.
Neuroblastoma
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002802
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Lymphoma, Non-Hodgkin's
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This is a pilot study to determine the overall survival rate and toxicities of obinutuzumab given with GDP chemotherapy for relapsed or refractory CD20+ aggressive non-Hodgkin lymphoma.
- Trial name
- NCT02750670
- Testing
- Obinutuzumab, Gemcitabine, Dexamethasone
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Pancreatic Adenocarcinoma
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
The objective of this study is to improve survival by the addition of anakinra to the chemotherapy combination of nab-paclitaxel, gemcitabine, and cisplatin in patients with resectable or potentially resectable pancreatic…
- Trial name
- NCT02550327
- Testing
- Nab-paclitaxel, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.